# Akeso's first-in-class PD-1/CTLA-4 bispecific antibody, in combination with chemotherapy as first-line treatment for advanced pancreatic ductal adenocarcinoma (PDAC) presented at the 2026 American Association for Cancer Research

*biotech · news · 2026-04-21 · The Manila Times*

## Key points

- Cadonilimab plus chemotherapy showed a median overall survival exceeding 23 months in locally advanced PDAC.
- Twelve-month overall survival rate reached 91.7% and 24-month rate was 44.1% for locally advanced disease.
- Objective response rate was 33.9% and disease control rate was 96.4% across the entire COMPASSION-26 population.
- No new safety signals were found, confirming the regimen's favorable and manageable safety profile.

**Companies:** Akeso
**Countries:** Hong Kong, China, United States

[Read the full story on The Manila Times](https://www.manilatimes.net/2026/04/21/tmt-newswire/pr-newswire/cadonilimab-combination-demonstrates-promising-survival-benefit-in-locally-advanced-pancreatic-cancer-phase-ii-compassion-26-data-presented-at-aacr-2026/2324511)

---

Canonical: https://newsio.io/n/cfcf2ab8-deb4-4a1e-8e19-136c8b9eb2e9/akesos-first-in-class-pd-1ctla-4-bispecific-antibody-in-combination-with-chemoth
Summarized by Newsio from The Manila Times. https://newsio.io/how-it-works